Muscle Relaxant Selection for Patients with Elevated LFTs
Use atracurium or cisatracurium (benzylisoquinoline muscle relaxants) in patients with elevated liver function tests or hepatic failure. 1
Preferred Agent: Benzylisoquinoline Compounds
Atracurium and cisatracurium are the muscle relaxants of choice because their elimination is largely organ-independent, making them ideal for hepatic dysfunction. 1
Why Benzylisoquinolines Are Superior in Hepatic Dysfunction:
Atracurium undergoes approximately 50% elimination through organ-independent Hofmann degradation and ester hydrolysis, with the remainder through metabolism or excretion, resulting in similar pharmacokinetics in patients with and without liver failure. 1
Cisatracurium is even more advantageous because its elimination is overwhelmingly non-enzymatic (one of ten atracurium isomers), and it maintains consistent pharmacokinetic and pharmacodynamic profiles regardless of hepatic function. 1
Cisatracurium generates significantly less laudanosine than atracurium due to higher potency requiring lower doses, though laudanosine accumulation does not reach clinically significant concentrations even with prolonged infusions. 1
Avoid or Use Cautiously: Rocuronium
Rocuronium is problematic in hepatic failure because it is primarily eliminated through urine and bile, leading to several complications: 1
Clearance is reduced in cirrhotic patients with wide variability in duration of action after repeated doses. 1, 2
Cirrhotic patients demonstrate a 2.4-fold higher ED50 (144 mcg/kg vs 60 mcg/kg in controls) due to increased volume of distribution (78.5 ml/kg vs 29.8 ml/kg). 2
Duration of action is prolonged (41 minutes vs 30 minutes to 25% recovery), with progressive prolongation after multiple maintenance doses. 2
Individual variability in response is markedly increased, making dosing unpredictable and potentially dangerous. 1, 2
Dosing Recommendations
Do not modify the initial intubating dose regardless of hepatic dysfunction or muscle relaxant chosen. 1
Standard intubating doses ensure adequate neuromuscular blockade during intubation because the time to onset remains unchanged even though duration of action may be prolonged. 1
In cirrhotic patients, the increased volume of distribution at lower doses reduces drug concentration, but this effect becomes clinically insignificant at standard intubating doses. 1
Maintenance dosing requires careful titration with neuromuscular monitoring, particularly for rocuronium where repeated doses show cumulative effects in cirrhosis. 2
Reversal Agent Considerations
Sugammadex can be administered at usual doses for reversal of steroidal muscle relaxants (rocuronium) even in hepatic failure. 1
Sugammadex is renally eliminated and accumulates in renal failure but not hepatic failure, making it safe for use in patients with elevated LFTs. 1
For benzylisoquinoline agents, traditional reversal with neostigmine is appropriate as these agents are the preferred choice in hepatic dysfunction. 1
Clinical Pitfalls to Avoid
Do not assume all muscle relaxants behave similarly in liver disease—the route of elimination is critical. 1, 3
Avoid repeated dosing of rocuronium without neuromuscular monitoring in cirrhotic patients due to unpredictable cumulative effects and prolonged duration. 2
In decompensated cirrhosis, prescribing practices require particular caution with drugs having predominant hepatic metabolism, especially those with narrow therapeutic indices. 4
Individual variability is substantially greater in hepatic failure populations, necessitating neuromuscular monitoring when available. 1, 2